FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033269533> ?p ?o ?g. }

• W3033269533 abstract "Abstract Background This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. Methods IMPACT was a 52-week, randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of FF/UMEC/VI 100/62.5/25 mcg with FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg in patients ≥40 years of age with symptomatic chronic obstructive pulmonary disease (COPD) and ≥1 moderate/severe exacerbation in the previous year. The inclusion criteria for the study were intentionally designed to permit the enrollment of patients with significant concurrent CV disease/risk. CV safety assessments included proportion of patients with and exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization/prolonged hospitalization or death. Results Baseline CV risk factors were similar across treatment groups. Overall, 68% of patients ( n = 7012) had ≥1 CV risk factor and 40% ( n = 4127) had ≥2. At baseline, 29% of patients reported a current/past cardiac disorder and 58% reported a current/past vascular disorder. The proportion of patients with on-treatment CVAESI was 11% for both FF/UMEC/VI and UMEC/VI, and 10% for FF/VI. There was no statistical difference for FF/UMEC/VI versus FF/VI or UMEC/VI in TTF CVAESI (hazard ratio [HR]: 0.98, 95% confidence interval [CI]: 0.85, 1.11; p = 0.711 and HR: 0.92, 95% CI: 0.78, 1.08; p = 0.317, respectively) nor TTF CVAESI leading to hospitalization/prolonged hospitalization or death (HR: 1.19, 95% CI: 0.93, 1.51; p = 0.167 and HR: 0.96, 95% CI: 0.72, 1.27; p = 0.760, respectively). On-treatment MACE occurred in ≤3% of patients across treatment groups, with similar prevalence and rates between treatments. Conclusions In a symptomatic COPD population with a history of exacerbations and a high rate of CV disease/risk, the proportion of patients with CVAESI and MACE was 10–11% and 1–3%, respectively, across treatment arms, and the risk of CVAESI was low and similar across treatment arms. There was no statistically significant increased CV risk associated with the use of FF/UMEC/VI versus FF/VI or UMEC/VI, and UMEC/VI versus FF/VI. Trial registration NCT02164513 (GSK study number CTT116855)." @default.
• W3033269533 created "2020-06-12" @default.
• W3033269533 creator A5003111166 @default.
• W3033269533 creator A5006589876 @default.
• W3033269533 creator A5009003396 @default.
• W3033269533 creator A5025358852 @default.
• W3033269533 creator A5026096786 @default.
• W3033269533 creator A5036734448 @default.
• W3033269533 creator A5038228413 @default.
• W3033269533 creator A5040853227 @default.
• W3033269533 creator A5045141623 @default.
• W3033269533 creator A5048374080 @default.
• W3033269533 creator A5051155080 @default.
• W3033269533 creator A5052717850 @default.
• W3033269533 creator A5055136088 @default.
• W3033269533 creator A5068917661 @default.
• W3033269533 creator A5071981916 @default.
• W3033269533 creator A5082568705 @default.
• W3033269533 date "2020-06-05" @default.
• W3033269533 modified "2023-10-02" @default.
• W3033269533 title "Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial" @default.
• W3033269533 cites W2032171019 @default.
• W3033269533 cites W2032176613 @default.
• W3033269533 cites W2042080482 @default.
• W3033269533 cites W2054931962 @default.
• W3033269533 cites W2065601647 @default.
• W3033269533 cites W2100520111 @default.
• W3033269533 cites W2122373621 @default.
• W3033269533 cites W2123477530 @default.
• W3033269533 cites W2134122420 @default.
• W3033269533 cites W2166386062 @default.
• W3033269533 cites W2344148139 @default.
• W3033269533 cites W2346277111 @default.
• W3033269533 cites W2462215050 @default.
• W3033269533 cites W2468772595 @default.
• W3033269533 cites W2513086234 @default.
• W3033269533 cites W2604743750 @default.
• W3033269533 cites W2606915282 @default.
• W3033269533 cites W2614242365 @default.
• W3033269533 cites W2617995139 @default.
• W3033269533 cites W2733442820 @default.
• W3033269533 cites W2773656553 @default.
• W3033269533 cites W2782011123 @default.
• W3033269533 cites W2785999277 @default.
• W3033269533 cites W2789802763 @default.
• W3033269533 cites W2794221242 @default.
• W3033269533 cites W2801185132 @default.
• W3033269533 cites W2802221596 @default.
• W3033269533 cites W2895246789 @default.
• W3033269533 cites W2910341328 @default.
• W3033269533 cites W2914614248 @default.
• W3033269533 cites W3011621519 @default.
• W3033269533 doi "https://doi.org/10.1186/s12931-020-01398-w" @default.
• W3033269533 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7275457" @default.
• W3033269533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32503599" @default.
• W3033269533 hasPublicationYear "2020" @default.
• W3033269533 type Work @default.
• W3033269533 sameAs 3033269533 @default.
• W3033269533 citedByCount "10" @default.
• W3033269533 countsByYear W30332695332020 @default.
• W3033269533 countsByYear W30332695332021 @default.
• W3033269533 countsByYear W30332695332022 @default.
• W3033269533 countsByYear W30332695332023 @default.
• W3033269533 crossrefType "journal-article" @default.
• W3033269533 hasAuthorship W3033269533A5003111166 @default.
• W3033269533 hasAuthorship W3033269533A5006589876 @default.
• W3033269533 hasAuthorship W3033269533A5009003396 @default.
• W3033269533 hasAuthorship W3033269533A5025358852 @default.
• W3033269533 hasAuthorship W3033269533A5026096786 @default.
• W3033269533 hasAuthorship W3033269533A5036734448 @default.
• W3033269533 hasAuthorship W3033269533A5038228413 @default.
• W3033269533 hasAuthorship W3033269533A5040853227 @default.
• W3033269533 hasAuthorship W3033269533A5045141623 @default.
• W3033269533 hasAuthorship W3033269533A5048374080 @default.
• W3033269533 hasAuthorship W3033269533A5051155080 @default.
• W3033269533 hasAuthorship W3033269533A5052717850 @default.
• W3033269533 hasAuthorship W3033269533A5055136088 @default.
• W3033269533 hasAuthorship W3033269533A5068917661 @default.
• W3033269533 hasAuthorship W3033269533A5071981916 @default.
• W3033269533 hasAuthorship W3033269533A5082568705 @default.
• W3033269533 hasBestOaLocation W30332695331 @default.
• W3033269533 hasConcept C126322002 @default.
• W3033269533 hasConcept C197934379 @default.
• W3033269533 hasConcept C207103383 @default.
• W3033269533 hasConcept C2776042228 @default.
• W3033269533 hasConcept C2776780178 @default.
• W3033269533 hasConcept C2779028295 @default.
• W3033269533 hasConcept C2780739214 @default.
• W3033269533 hasConcept C44249647 @default.
• W3033269533 hasConcept C45393284 @default.
• W3033269533 hasConcept C500558357 @default.
• W3033269533 hasConcept C71924100 @default.
• W3033269533 hasConcept C90924648 @default.
• W3033269533 hasConceptScore W3033269533C126322002 @default.
• W3033269533 hasConceptScore W3033269533C197934379 @default.
• W3033269533 hasConceptScore W3033269533C207103383 @default.
• W3033269533 hasConceptScore W3033269533C2776042228 @default.
• W3033269533 hasConceptScore W3033269533C2776780178 @default.
• W3033269533 hasConceptScore W3033269533C2779028295 @default.
• W3033269533 hasConceptScore W3033269533C2780739214 @default.

• next